Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Corcept Therapeutics Incorporated (CORT) vs Summit Therapeutics PLC (SMMT)

Corcept Therapeutics Incorporated and Summit Therapeutics PLC are both Biotechnology companies. Corcept Therapeutics Incorporated and Summit Therapeutics PLC are of similar size ($13.1B and $12.9B). Summit Therapeutics PLC has negative trailing earnings, so its P/E is not meaningful; Corcept Therapeutics Incorporated trades at 223×. Corcept Therapeutics Incorporated grew revenue faster over the last twelve months: 16.0% against −61.0%. Corcept Therapeutics Incorporated has the higher net margin (6.53% vs 0.00%) and the higher return on invested capital (1.01% vs 0.00%). Across the 18 metrics below, Corcept Therapeutics Incorporated leads on 15 and Summit Therapeutics PLC on 3.

Valuation

Metric CORT SMMT Biotechnology median
P/E 223.27 n/m 7.88
P/S 14.73 17,230.45 11.47
P/B 17.33 19.28 2.52
Price to free cash flow 114.42 n/m 21.16
EV/EBITDA 3,205.62 n/m 0.74
EV/Sales 14.36 16,392.16 10.73
Earnings yield 0.45% (7.17%) (28.84%)
Free cash flow yield 0.87% (3.79%) (23.03%)

Profitability

Metric CORT SMMT Biotechnology median
Gross margin 98.30% 100.00% 65.16%
Operating margin 0.77% 0.00% 0.00%
Net margin 6.53% 0.00% 0.00%
Free cash flow margin 12.87% 0.00% 0.00%
Return on equity 8.08% (192.50%) (57.72%)
Return on assets 6.41% (159.09%) (49.22%)
Return on invested capital 1.01% 0.00% 0.00%

Growth

Metric CORT SMMT Biotechnology median
Revenue growth (TTM) 16.02% (61.03%) 5.64%
EPS growth (last fiscal year) (33.33%) (364.52%) —
Revenue growth, 5-year CAGR 16.56% (46.49%) 8.40%
Net income growth, 5-year CAGR (1.52%) 0.00% 0.00%

Health

Metric CORT SMMT Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 2.86 6.96 4.73
Net debt to EBITDA (8.83) 0.65 0.96

Dividend

Metric CORT SMMT Biotechnology median
Dividend yield 0.31% — 2.10%
Payout ratio 0.00 0.00 0.00

Size

Metric CORT SMMT Biotechnology median
Market cap 12.87b 13.12b 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack